Abstract
The alkylating agents, in combination with other antineoplastic agents or radiation, are frequently used in preparative regimens for conventional hematopoietic stem cell transplantation (HSCT). The alkylating agents are well suited for preparative regimens for HSCT because of their activity against a number of tumor types; a relative lack of cross-resistance among these agents; and because myelosuppression is frequently the dose-limiting toxicity at standard doses. 1 Data from pre-clinical models indicate that the degree of tumor-cell kill is directly proportional to the dose of an alkylating agent, suggesting that the 2-20 fold dose-escalation achieved through the use of HSCT may improve response rates 2,3 However, there are substantial toxicities associated with the preparative regimens that include alkylating agents
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
